The US Department of Justice's Civil Rights Division has been examining admissions practices at Yale School of Medicine, in an inquiry that centres on whether the institution used race as a factor when selecting applicants. The review, reported in mid-May 2026, follows the Supreme Court's 2023 decision limiting race-conscious admissions and forms part of a wider federal effort to test how universities have responded to that ruling. As an ongoing enforcement matter, the position of the parties is still developing and no independent adjudication has been recorded.
What the inquiry concerns
The Department of Justice has focused on the medical school's admissions processes and the extent to which race featured in decisions about which candidates were offered places. According to the department, the review considered internal documents and followed a year-long assessment of Yale's policies and practices. Federal officials have indicated that they looked at whether the institution adopted alternative selection methods intended to sustain particular demographic outcomes after the 2023 judgment took effect. The department has described its assessment of academic qualifications across different applicant groups as part of this analysis.
The legal backdrop
The inquiry rests on federal civil rights law, in particular Title VI of the Civil Rights Act, which prohibits discrimination on the basis of race in programmes that receive federal funding. It also draws on the Supreme Court's 2023 ruling in the cases involving Harvard University and the University of North Carolina, which curtailed the use of race as an explicit factor in university admissions. That decision reshaped the compliance landscape for higher education across the United States, and enforcement bodies have since scrutinised how institutions structure their selection criteria. The Yale matter is being watched as an early test of how those principles are applied to professional and graduate schools.
Statements from the department
Assistant Attorney General Harmeet K. Dhillon indicated that the department would continue examining medical schools and universities said to be using alternative approaches to maintain race-conscious outcomes. The remarks signalled that the Yale review sits within a broader programme of scrutiny rather than a single, isolated case. Yale School of Medicine's formal response to the department's characterisation of its practices has not been detailed in the available reporting, and any conclusions attributed to the review remain the department's own account of the matter.
Where matters stand
At the reported stage, the inquiry reflects the department's assessment of Yale's admissions practices following its review. As with any enforcement process, the framing of documents, statistics and internal communications may be contested, and institutions typically have the opportunity to respond, provide context or challenge the interpretation placed on their records. The practical consequences for Yale, including any negotiated resolution or further steps, had not been finalised in the material reviewed for this report.
For the wider sector, the inquiry underlines the compliance pressure now facing universities as regulators examine how the 2023 ruling is being observed in practice. Institutions may respond by revisiting their admissions documentation, the language used in internal guidance and the metrics on which selection decisions rest. Advisers to higher education bodies are likely to monitor the Yale matter closely, as its handling could shape expectations for how universities demonstrate that their processes align with federal civil rights obligations in the years ahead.
